Zacks: Brokerages Anticipate Nektar Therapeutics (NKTR) Will Post Quarterly Sales of $26.07 Million

Share on StockTwits

Wall Street analysts forecast that Nektar Therapeutics (NASDAQ:NKTR) will announce sales of $26.07 million for the current quarter, Zacks reports. Five analysts have issued estimates for Nektar Therapeutics’ earnings. The highest sales estimate is $42.50 million and the lowest is $18.50 million. Nektar Therapeutics reported sales of $95.47 million in the same quarter last year, which would suggest a negative year over year growth rate of 72.7%. The business is scheduled to announce its next quarterly earnings report on Thursday, March 7th.

On average, analysts expect that Nektar Therapeutics will report full-year sales of $1.18 billion for the current fiscal year, with estimates ranging from $1.17 billion to $1.20 billion. For the next year, analysts forecast that the firm will report sales of $383.90 million, with estimates ranging from $92.39 million to $1.18 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that cover Nektar Therapeutics.

A number of brokerages recently issued reports on NKTR. Zacks Investment Research downgraded shares of Nektar Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, December 10th. TheStreet downgraded shares of Nektar Therapeutics from a “c” rating to a “d+” rating in a report on Wednesday, November 7th. ValuEngine downgraded shares of Nektar Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, November 16th. Canaccord Genuity lowered their price target on shares of Nektar Therapeutics from $94.00 to $86.00 and set a “buy” rating on the stock in a report on Tuesday, November 13th. Finally, HC Wainwright set a $47.00 price target on shares of Nektar Therapeutics and gave the stock a “hold” rating in a report on Monday, November 12th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have given a buy rating to the company. Nektar Therapeutics currently has a consensus rating of “Buy” and an average price target of $79.90.

NASDAQ NKTR traded up $1.46 during mid-day trading on Monday, reaching $46.35. 1,697,512 shares of the stock were exchanged, compared to its average volume of 1,789,996. Nektar Therapeutics has a 1 year low of $29.22 and a 1 year high of $111.36. The company has a market capitalization of $7.77 billion, a PE ratio of -84.27 and a beta of 3.03. The company has a debt-to-equity ratio of 0.14, a quick ratio of 13.80 and a current ratio of 13.93.

In other Nektar Therapeutics news, SVP Jillian B. Thomsen sold 16,119 shares of the company’s stock in a transaction on Monday, February 4th. The shares were sold at an average price of $42.16, for a total transaction of $679,577.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Stephen K. Doberstein sold 4,524 shares of the company’s stock in a transaction on Friday, November 16th. The stock was sold at an average price of $38.25, for a total transaction of $173,043.00. Following the transaction, the senior vice president now owns 78,734 shares of the company’s stock, valued at $3,011,575.50. The disclosure for this sale can be found here. Insiders have sold 115,482 shares of company stock valued at $4,768,122 over the last 90 days. 4.31% of the stock is currently owned by company insiders.

A number of large investors have recently bought and sold shares of the business. Laurel Wealth Advisors LLC acquired a new stake in shares of Nektar Therapeutics in the fourth quarter valued at about $39,000. Sandy Spring Bank acquired a new stake in shares of Nektar Therapeutics in the fourth quarter valued at about $59,000. Financial Architects Inc raised its position in shares of Nektar Therapeutics by 91.6% in the fourth quarter. Financial Architects Inc now owns 2,092 shares of the biopharmaceutical company’s stock valued at $69,000 after buying an additional 1,000 shares during the last quarter. Essex Investment Management Co. LLC acquired a new stake in shares of Nektar Therapeutics in the fourth quarter valued at about $101,000. Finally, Belpointe Asset Management LLC acquired a new stake in shares of Nektar Therapeutics in the third quarter valued at about $123,000. Institutional investors own 91.26% of the company’s stock.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.

Featured Article: How are institutional investors different from individual investors?

Get a free copy of the Zacks research report on Nektar Therapeutics (NKTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Dril-Quip, Inc.  Stake Lifted by Dupont Capital Management Corp
Dril-Quip, Inc. Stake Lifted by Dupont Capital Management Corp
Dupont Capital Management Corp Sells 2,843 Shares of Rexford Industrial Realty Inc
Dupont Capital Management Corp Sells 2,843 Shares of Rexford Industrial Realty Inc
Dupont Capital Management Corp Sells 18,247 Shares of Unum Group
Dupont Capital Management Corp Sells 18,247 Shares of Unum Group
Schlumberger Limited.  Shares Sold by Eads & Heald Wealth Management
Schlumberger Limited. Shares Sold by Eads & Heald Wealth Management
Diligent Investors LLC Sells 9,128 Shares of Merck & Co., Inc.
Diligent Investors LLC Sells 9,128 Shares of Merck & Co., Inc.
Cypress Capital Management LLC Sells 847 Shares of Vanguard Large-Cap ETF
Cypress Capital Management LLC Sells 847 Shares of Vanguard Large-Cap ETF


Leave a Reply

© 2006-2019 Ticker Report